Comparative Analysis of Investment Potential of Leading Pharmaceutical Companies

This research paper aims to address the research question of identifying the most promising investment target among four leading pharmaceutical companies: Merck (MRK), Pfizer (PFE), Johnson & Johnson (JNJ), and Novartis AG (NVS). The study seeks to provide investors with valuable insights into the financial performance and investment potential of these industry giants, guiding them towards informed decision-making. In the academic field, this research contributes to the understanding of how financial metrics can be utilized to evaluate investment opportunities in the pharmaceutical sector, offering practical implications for investors and researchers alike. The methods employed in this study involved a comprehensive analysis of key financial indicators, including earnings per share (EPS), price-to-earnings (P/E) ratio, and profitability ratios such as gross profit margin and gross profit-to-assets (GP/A) ratio. By examining these metrics, the research aimed to assess the relative strengths and weaknesses of each company and determine the most attractive investment option among the four pharmaceutical giants. The results of the analysis revealed Pfizer (PFE) as the recommended investment target based on its lower P/E ratio, favorable PEG ratio, strong EPS growth rate, and improving net profit margin. This finding suggests that Pfizer presents a compelling investment opportunity in the pharmaceutical sector, offering potential for growth and financial stability. The implications of this research extend to investors seeking to navigate the complexities of the pharmaceutical industry, providing them with actionable insights to make informed investment decision.